Our take on the latest news and views on data.

Relevant company news, articles, podcasts, and blog posts.

Recent Posts

Recent Tweets

$RCUS Taiho Pharmaceutical intends to obtain exclusive rights to Quemliclustat in Japan and some Asian territories through an option exercise.

More Info: https://pryzm.ozmosi.com/product/20934 $XBI $IBB $XPH $PPH

$RVMD Revolution Medicines will give an update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024.

More Info: https://pryzm.ozmosi.com/product/25618 $XBI $IBB $XPH $PPH

$KYMR Kymera to expand KT-474 (SAR444656) HS and AD Phase 2 studies after interim safety and efficacy review.

More Info: https://pryzm.ozmosi.com/product/20894 $XBI $IBB $XPH $PPH


$HCM Sovleplenib - Phase III ESLIM-01 and Phase II/III ESLIM-02 studies of Syk inhibitor sovleplenib in immune thrombocytopenia ("ITP") and warm antibody autoimmune hemolytic anemia, ("wAIHA") respectively.

Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

600 Warren Ave,
Spring Lake, NJ 07762